Background & Aims Over the last decade, clinical experiences and research studies raised
concerns regarding use of proton pump inhibitors (PPIs) as part of the diagnostic strategy for …

Eosinophilic esophagitis is an emerging disease that is distinguished from
gastroesophageal reflux disease by the expression of a unique esophageal transcriptome …

Background Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and
interleukin-13 signaling, which have key roles in eosinophilic esophagitis. Methods We …

Background Dupilumab is a human monoclonal antibody that blocks interleukin-4 and
interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by …

Background Eosinophilic oesophagitis (EoE) is an increasingly common cause of dysphagia
in both children and adults, as well as one of the most prevalent oesophageal diseases with …

1 ESGE recommends that, where there is a suspicion of eosinophilic esophagitis, at least six
biopsies should be taken, two to four biopsies from the distal esophagus and two to four …

Background & Aims Disease activity and severity of eosinophilic esophagitis (EoE) dictate
therapeutic options and management, but the decision-making process for determining …

Background The frequency of eosinophilic oesophagitis (EoE) occurrence is escalating.
Current diagnostic criteria recently proposed for the disease, determine that previous …

Background & Aims Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder.
Swallowed topical-acting corticosteroids are effective in bringing active EoE into remission …

Background & Aims Swallowed topical-acting corticosteroids are recommended as first-line
therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized for …